B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co

Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]

Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast

Leap by McKinsey Research Shows 50 Percent of Global Revenue Will

In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable

B. Braun

Where do lawsuits against B. Braun over cancer-causing chemical stand?

Dental disaster: One year after first lockdowns dentists around the

Nouvelles officielles de Cooperation 2024

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

Organization, Facts & Figures

Intravenous Equipment Market Study & Sales Statistics Report